iBio, Inc. (NYSEMKT:IBIO) Files An 8-K Other Events
Item 8.01
On October 25, 2019, the Company issued a press release announcing the pricing of a public offering of securities. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
| 99.1 | Press Release, dated October 25, 2019, issued by iBio, Inc. |
iBio, Inc. Exhibit
EX-99.1 2 tv531270_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 IBIO,…
To view the full exhibit click here
About iBio, Inc. (NYSEMKT:IBIO)
iBio, Inc. is a biotechnology company. The Company is focused on commercializing its technologies and product candidates and providing product development and manufacturing services to clients and collaborators. Its technologies include iBioLaunch technology and iBioModulator. The Company’s technologies constitute a transformative platform for development and production of biologics in hydroponically grown green plants. The Company is focused on the commercialization of its plant-based protein expression technologies for vaccines and therapeutic proteins and on developing and commercializing select biopharmaceutical product candidates. The Company’s technology is applicable in a range of product candidates, including products against fibrotic diseases, vaccines, enzyme replacements, monoclonal antibodies, and recombinant versions of marketed products that are derived from human blood plasma.
